Quote | Xilio Therapeutics Inc. (NASDAQ:XLO)
Last: | $0.89 |
---|---|
Change Percent: | -2.82% |
Open: | $0.95 |
Close: | $0.89 |
High: | $0.959999 |
Low: | $0.86 |
Volume: | 366,297 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Xilio Therapeutics Inc. (NASDAQ:XLO)
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Aoife Brennan, M.D., and James Sh...
2024-05-14 13:54:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xilio Therapeutics (NASDAQ: XLO ) just reported results for the first quarter of 2024. Xilio Therapeutics reported earnings per share of -59 cents. This was below the anal...
Message Board Posts | Xilio Therapeutics Inc. (NASDAQ:XLO)
Subject | By | Source | When |
---|---|---|---|
Price target > 36.00 > HC Wainwright | crudeoil24 | investorshub | 02/10/2022 8:10:07 PM |
TODAY > Xilio Therapeutics, Inc. (Nasdaq: XLO), a | crudeoil24 | investorshub | 02/10/2022 6:56:10 PM |
Xilio Therapeutics, Inc. is a biotechnology company. The | crudeoil24 | investorshub | 02/10/2022 6:51:56 PM |
News, Short Squeeze, Breakout and More Instantly...
Xilio Therapeutics Inc. Company Name:
XLO Stock Symbol:
NASDAQ Market:
Xilio Therapeutics Inc. Website:
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Aoife Brennan, M.D., and James Sh...
Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Plan to report clinical data for XTX101 and XTX301, a tumor-a...